Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | TKT | P29401 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745069 | 1.00 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL14127591 | 0.98 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL21649925 | 0.81 | KDM4E (0.39) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL25371113 | 0.79 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL30303053 | 0.79 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL830696 | 0.79 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL2253996 | 0.77 | KDM4E (0.40) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL14955141 | 0.77 | MAT2A (0.42) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E | |
| SCHEMBL17986994 | 0.77 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1TRPV4KDM4EHSD17B10 | |
| SCHEMBL29505062 | 0.77 | MAT2A (0.42) | HSP90AA1HSP90AB1TRPV4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559908-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | S2CBio Inc. (KR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024058617-A1 | ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND | 일동제약(주) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3257853-B1 | CONDENSED HETEROCYCLIC COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT | NISSAN CHEMICAL CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| EP-1957078-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064932-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-4082845-A | SEROTONINMIMETICS USEFUL AS ANORECTIC, ANTIDEPRESSANT, ANALGESIC AND HYPNOTIC AGENTS | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | HSP90AA1 887/4885HSP90AB1 958/4885TRPV4 4867/4885 |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | HSP90AA1 606/4885HSP90AB1 424/4885TRPV4 4/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HSP90AA1 819/4885HSP90AB1 599/4885TRPV4 4/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | HSP90AA1 2150/4885HSP90AB1 1373/4885TRPV4 2923/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | HSP90AA1 1230/4885HSP90AB1 1339/4885TRPV4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.